EP Patent

EP1558231A4 — Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders

Assigned to Cypress Bioscience Inc · Expires 2010-09-08 · 16y expired

What this patent protects

Patent listed against milnacipran-hydrochloride.

Drugs covered by this patent

milnacipran-hydrochloride (MILNACIPRAN HYDROCHLORIDE)

Patent Metadata

Patent number: EP1558231A4
Jurisdiction: EP
Classification: —
Expires: 2010-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Cypress Bioscience Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.